|
Patent landscape, scope, and claims: |
Analysis of United States Patent 9,827,231: Scope, Claims, and Landscape
United States Patent 9,827,231, granted on November 28, 2017, to Bristol-Myers Squibb Company, covers pharmaceutical compositions and methods for treating cancer. The patent's claims focus on specific formulations of nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, intended to enhance stability and efficacy. The patent landscape surrounding this intellectual property is characterized by significant activity in the immuno-oncology space, with numerous related patents and ongoing litigation.
What Does Patent 9,827,231 Claim?
The patent claims in US 9,827,231 broadly cover pharmaceutical compositions and methods of treatment.
What are the core compositions claimed?
The primary focus of the patent is on pharmaceutical compositions containing nivolumab. These compositions are characterized by specific parameters designed to ensure product stability and therapeutic benefit.
- Nivolumab Concentration: The claims define specific ranges for the concentration of nivolumab. For example, certain embodiments specify a nivolumab concentration of about 10 mg/mL to about 50 mg/mL.
- Excipient Content: The patent details the inclusion and concentration of various excipients crucial for formulation stability. This includes:
- Buffering Agents: Specific buffering agents and their concentrations are claimed to maintain pH. Examples include citrate buffers and histidine buffers within defined pH ranges, typically between pH 5.5 and 7.5.
- Stabilizers: The use of specific stabilizers like sugars (e.g., sucrose, trehalose) and amino acids (e.g., glycine, arginine) is claimed to prevent protein aggregation and degradation. Specific concentration ranges are often provided, such as sucrose concentrations from 5% to 15% w/v.
- Surfactants: Non-ionic surfactants, such as polysorbate 80 or polysorbate 20, are claimed at low concentrations (e.g., 0.01% to 0.1% w/v) to minimize protein adsorption to container surfaces and prevent foaming.
- Formulation pH: Claims also specify the pH range of the final composition, typically between pH 6.0 and 7.0, to optimize nivolumab stability.
- Absence of Certain Components: Some claims explicitly exclude certain components to differentiate the claimed invention from prior art formulations.
What methods of treatment are covered?
Beyond the composition, patent 9,827,231 also claims methods of treating cancer using these specific nivolumab formulations.
- Cancer Types: The claims encompass the treatment of various solid tumors and hematological malignancies. This includes, but is not limited to, melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal cancer, and Hodgkin lymphoma.
- Dosage Regimens: While not always specifying exact dosage amounts, the claims cover administering the pharmaceutical composition in therapeutically effective amounts. This implies established or novel dosing schedules for nivolumab.
- Administration Routes: The patent primarily implies intravenous administration, a standard route for monoclonal antibody therapies.
What are the key differentiators of the claimed invention?
The patent distinguishes itself by focusing on a stable liquid formulation of nivolumab.
- Improved Stability: The primary advantage highlighted is enhanced stability, measured by reduced aggregation and degradation of nivolumab over extended storage periods and under various stress conditions (e.g., freeze-thaw cycles, elevated temperatures). This is achieved through the specific combination and concentration of excipients.
- Ready-to-Use Formulation: The formulations are often designed for direct administration or minimal reconstitution, improving convenience for healthcare providers and potentially reducing errors.
- Therapeutic Equivalence: While enhancing stability, the formulations aim to maintain or improve the therapeutic efficacy of nivolumab compared to less stable or different formulations.
What is the patent landscape for US 9,827,231?
The patent landscape for US 9,827,231 is complex, situated within the highly competitive field of immuno-oncology, particularly for PD-1 inhibitors like nivolumab.
Who are the key players in the PD-1 inhibitor space?
Several major pharmaceutical companies hold significant patent portfolios related to PD-1 inhibitors, including nivolumab and its competitors.
- Bristol-Myers Squibb (BMS): As the assignee of US 9,827,231, BMS is a central player. Their patent strategy encompasses the drug substance itself, various formulations, manufacturing processes, and methods of use for nivolumab.
- Merck & Co.: A leading competitor with its PD-1 inhibitor, pembrolizumab (Keytruda). Merck holds numerous patents covering its drug, formulations, and therapeutic applications.
- Roche: Holds patents related to atezolizumab, a PD-L1 inhibitor, which targets a related pathway in cancer immunotherapy.
- AstraZeneca: Has patents related to durvalumab, another PD-L1 inhibitor.
- Other Biopharmaceutical Companies: Numerous smaller companies and academic institutions are also active, developing novel immuno-oncology agents or targeting different aspects of the immune response.
What types of patents exist in this area?
The patent landscape is diverse, covering various aspects of drug development and commercialization.
- Composition of Matter Patents: These are the most fundamental, covering the active pharmaceutical ingredient (API) itself (e.g., the nivolumab antibody sequence). These often have the longest patent life.
- Formulation Patents: Like US 9,827,231, these patents cover specific pharmaceutical compositions, including the API and its excipients, designed for improved stability, delivery, or efficacy.
- Method of Treatment Patents: These patents claim the use of a particular drug for treating specific diseases or conditions, often specifying patient populations or treatment regimens.
- Manufacturing Process Patents: These patents protect novel or improved methods for producing the drug substance or drug product.
- Polymorph Patents: For small molecules, patents can claim specific crystalline forms (polymorphs) that offer advantages in manufacturing or bioavailability.
- Combination Therapy Patents: Patents covering the use of a drug in combination with other therapeutic agents.
What is the patent protection timeline for nivolumab and related technologies?
The patent protection timeline for a drug like nivolumab is multifaceted, with different patents expiring at different times.
- Core Compound Patents: The initial patents covering the nivolumab antibody sequence itself likely have expired or are nearing expiration. These are typically filed early in the drug discovery process.
- Formulation and Method Patents: Patents like US 9,827,231, covering specific formulations and methods of use, extend the period of market exclusivity. These are often filed later in development or after initial approval. The lifespan of these patents is crucial for continued market protection. For US 9,827,231, the patent term is generally 20 years from the filing date, subject to adjustments for patent term extension (PTE) and other regulatory factors.
- Patent Term Extension (PTE): The US patent system allows for PTE to compensate for some of the time lost during the regulatory review process. This can extend the life of key patents.
- Exclusivity under Hatch-Waxman Act: For approved drugs, the FDA grants various periods of market exclusivity independent of patents (e.g., 5 years for new chemical entities, 3 years for new clinical investigations).
Are there any known challenges or litigations involving US 9,827,231 or related patents?
The immuno-oncology field is rife with patent litigation as companies vigorously defend their market exclusivity and challenge competitors.
- Infringement Lawsuits: Bristol-Myers Squibb has been involved in numerous patent litigations concerning Opdivo (nivolumab) and its associated intellectual property. These often involve challenges to formulation patents or method-of-treatment patents by generic or biosimilar manufacturers seeking to enter the market.
- Inter Partes Review (IPR): Competitors may file IPR petitions with the U.S. Patent and Trademark Office (USPTO) challenging the validity of key patents, including formulation patents like US 9,827,231, arguing they are obvious or not novel based on prior art.
- Biosimilar Competition: The advent of biosimilar versions of monoclonal antibodies leads to intense scrutiny of innovator patents. Companies developing biosimilars will often seek to invalidate or design around existing patents.
- Claim Scope Interpretation: Litigation frequently centers on the precise interpretation of patent claims. Disputes can arise over whether a competitor's product or process infringes on the specific wording and scope of the claims in patents like US 9,827,231.
Key Takeaways
- United States Patent 9,827,231 protects specific liquid formulations of nivolumab, characterized by defined concentrations of the drug and tailored excipients to enhance stability and therapeutic delivery.
- The patent claims cover both the pharmaceutical compositions and methods for treating various cancers using these formulations.
- The patent landscape for PD-1 inhibitors, including nivolumab, is highly competitive, dominated by major pharmaceutical players and characterized by extensive patent portfolios covering compounds, formulations, and methods of use.
- Bristol-Myers Squibb, as the assignee, holds significant intellectual property for nivolumab, with patents like US 9,827,231 contributing to its market exclusivity.
- The field is subject to considerable patent litigation and challenges, particularly as biosimilar competition emerges, making the scope and validity of formulation patents critical.
Frequently Asked Questions
-
What is the primary benefit of the formulations claimed in US 9,827,231 over earlier nivolumab formulations?
The primary benefit is enhanced stability, reducing protein aggregation and degradation, which is crucial for maintaining efficacy and extending shelf life.
-
Does US 9,827,231 cover the active pharmaceutical ingredient nivolumab itself?
No, this patent focuses on the pharmaceutical compositions and methods of treatment using nivolumab, not the underlying antibody sequence which would be covered by separate composition of matter patents.
-
What types of cancers are intended to be treated by the methods claimed in this patent?
The patent claims cover the treatment of a broad range of cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and others.
-
How long is the patent protection for US 9,827,231 expected to last?
The patent term is typically 20 years from the filing date, but can be extended through mechanisms like Patent Term Extension (PTE) to compensate for regulatory delays. The specific remaining term depends on the patent's filing date and any extensions granted.
-
Could a generic or biosimilar version of nivolumab be developed without infringing on US 9,827,231?
This depends on whether the generic or biosimilar manufacturer can formulate nivolumab in a way that does not fall within the specific claims of US 9,827,231 or can successfully challenge the patent's validity. Developing an alternative stable formulation could avoid infringement.
Citations
[1] Bristol-Myers Squibb Company. (2017). Pharmaceutical compositions and methods for treating cancer. U.S. Patent 9,827,231. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
